ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Myricetin ameliorates letrozole-induced PCOS in female rats-a mechanistic approach through in silico, in vitro, and in vivo study via P13/AKT and NF-κB pathway crosstalk.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding polycystic ovary syndrome: an integrated review of epidemiology, molecular mechanisms, animal models, and the expanding therapeutic landscape.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovarian syndrome (PCOS) is one of the leading causes of abnormalities in young female patients. Myricetin is flavonoid which has multiple pharmacological effects like anti-inflammatory, antidiabetic, and anticancer. This study determined the effect of myricetin in the treatment of PCOS. For in silico studies, network pharmacology and molecular docking and simulation were done through multiple software tools. In vitro evaluation was done through antioxidant assays (DPPH and ABTS). Female Sprague Dawley rats were used in six groups. Letrozole (1 mg/kg) in 0.5% CMC was used to induce PCOS for 21 days, while CMC was the only treatment given to the normal control. Metformin (20 mg/kg) or myricetin (75, 150, and 300 mg/kg) was administered for 15 days. On day 37, ovarian tissues were homogenized for antioxidant tests and RT-qPCR gene expression analysis, reproductive organs were gathered for histology, and blood was processed for ELISA and LFTs. Network pharmacology shows significant effects of myricetin within the body; however, molecular docking and simulation studies show that Protein kinase B (AKT) has a greater binding capacity with myricetin. It also shows maximum antioxidant activity through antioxidant assays. Myricetin's safety was validated by biochemical, oxidative stress, and histopathological analyses. It enhanced follicular structures and significantly reduced body weight and ovarian cysts. By lowering testosterone (0.265 ± 0.021 mIU/mL vs. 0.735 ± 0.14), LH (0.518 ± 0.009 vs. 2.005 ± 0.027), insulin (11.56 ± 0.40 vs. 29.21 ± 0.59), and corticosterone (51.8 ± 0.79 vs. 115.5 ± 2.9), while increasing FSH (0.87 ± 0.30 mIU/mL vs. 0.36 ± 0.04), myricetin restored antioxidant status. Gene expression analysis shows higher level of PCOS-related genes. Given that these effects were similar to those of metformin, myricetin appears to be a promising treatment option for PCOS.
Indexed as
Identifiers
41263995What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.